by drgitt | Jun 7, 2021 | Uncategorized
For Immediate Release: June 07, 2021 Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway,...
by drgitt | Jun 3, 2021 | Uncategorized
People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decades, although viral variants could dampen some of the protection they offer. Ewen Callaway A bone-marrow plasma cell (artificially coloured). Such cells, which...
by drgitt | May 8, 2021 | Uncategorized
Do you suffer from at least 6 migraine attacks a month? If so, you may be a candidate for a clinical drug trial testing a new form of botulinum toxin. Arizona Neuroscience Research at CNS is participating in this important trial. Drs. Gitt and Zuniga are investigators...
by drgitt | Apr 2, 2021 | Uncategorized
https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance
by drgitt | Apr 2, 2021 | Uncategorized
https://www.nationalmssociety.org/For-Professionals/Clinical-Care/COVID-19/COVID-19-Vaccine This is the National MS Society statement on vaccines for patients with MS taking disease modifying therapies.
by drgitt | Mar 19, 2021 | Uncategorized
Based on expert consensus and available data, we offer the following guidance regarding COVID-19 vaccination for people on MS disease modifying therapies (DMTs). This guidance will be updated as new data are available.The Pfizer BioNTech, Moderna and Janssen/J&J...
